Cochrane · systematic review · CD013318
Fenofibrate for diabetic retinopathy
Kataoka, SY, Lois, N, Kawano, S, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
Eyes and VisionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
4
No studies
3
Included studies
NR
No studies 3 · 42.9%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 42.9%High 1 · 14.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Fenofibrate for diabetic retinopathy
Population: people with type 2 diabetes
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Progression of DRa | RR 0.86 [0.6, 1.25] | 1 study · 1012 participants | Moderate Downgraded: imprecision |
Incidence of overt retinopathya,b | RR 0.91 [0.76, 1.09] | 2 studies · 1580 participants | Moderate Downgraded: imprecision |
Incidence of a reduction in visual acuity of 10 ETDR letters or more | no estimate extracted | NR | No studies |
Incidence of PDR | no estimate extracted | NR | No studies |
Incidence of DMOa | RR 0.39 [0.12, 1.24] | 1 study · 850 participants | Moderate Downgraded: imprecision |
Mean vision‐related quality of life | no estimate extracted | NR | No studies |
SAEa | RR 1.55 [1.05, 2.27] | 2 studies · 15226 participants | High |